Category NEWS

Gabrail Cancer

Gabrail Cancer Center Launches Study of Elranatamab and Low-Dose Lenalidomide Combination

The Gabrail Cancer Center Undertakes Investigator-Initiated Study Evaluating the T-Cell Engager Elranatamab in Combination with Starton Therapeutics’ Controlled Low-Dose Lenalidomide The Gabrail Cancer and Research Center, a PhaseWell Research site, announced that Nashat Gabrail, M.D., has received notification from the…

Read MoreGabrail Cancer Center Launches Study of Elranatamab and Low-Dose Lenalidomide Combination
Naturmega

Naturmega to Debut SUPRIAX2™ Solution in North America at SupplySide Global 2026

Naturmega’s SUPRIAX2™ Solution to Make Its North American Debut at SupplySide Global 2026 Naturmega, an advanced lipid science company specializing in omega-3 and next-generation lipid technologies, will introduce SUPRIAX2™ to the North American market at SupplySide Global 2026 in Las…

Read MoreNaturmega to Debut SUPRIAX2™ Solution in North America at SupplySide Global 2026
Yangi

Yangi Brings Cellera® Dry-Forming Technology to U.S. Converters Amid Tariff Changes

As Tariffs Reshape the Molded Fiber Market, Yangi Brings Its Dry-Forming Technology Cellera® to U.S. Converters Yangi, the Swedish developer of Cellera®, a dry-forming technology for fiber-based packaging, is entering the U.S. market with its quick-serve packaging range, as part of…

Read MoreYangi Brings Cellera® Dry-Forming Technology to U.S. Converters Amid Tariff Changes
Agenus

Agenus Reports Promising NEST Phase 2 Results Showing Deep Pathologic Responses in Resectable Colon Cancer

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer Agenus , a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase…

Read MoreAgenus Reports Promising NEST Phase 2 Results Showing Deep Pathologic Responses in Resectable Colon Cancer
Ivonescimab

Ivonescimab Plus Chemotherapy Shows Survival Benefit in Advanced Biliary Tract Cancer

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China Summit Therapeutics Inc. noted that its partner Akeso Inc. announced positive topline…

Read MoreIvonescimab Plus Chemotherapy Shows Survival Benefit in Advanced Biliary Tract Cancer
Maxis

Maxis AI Launches First Verticalized Context Layer to Enable Reliable, Cost-Efficient, and Compliant AI for Life Sciences

Maxis AI Introduces the First Verticalized Context Layer for Life Sciences, a Governed Execution Fabric That Makes Enterprise AI Reliable, Cost-Efficient, and Regulatory Compliant Maxis AI  introduced MaxisAI Holarchy, its Verticalized Context Layer, a governed institutional memory that gives life sciences…

Read MoreMaxis AI Launches First Verticalized Context Layer to Enable Reliable, Cost-Efficient, and Compliant AI for Life Sciences
Lōkahi Therapeutics™

Lōkahi Therapeutics Expands ai² Futures Lab Asset Network Through Continued University of Georgia Collaboration

Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. announced the continued participation of the University of Georgia’s Student Industry Fellows Program in the ai²…

Read MoreLōkahi Therapeutics Expands ai² Futures Lab Asset Network Through Continued University of Georgia Collaboration
Cardio

Cardio Diagnostics Launches In-House Testing at New CLIA-Certified Iowa Laboratory

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City Cardio Diagnostics Holdings, Inc. an AI-driven precision cardiovascular medicine company, announced the official launch of its in-house, high complexity CLIA-certified laboratory in Iowa City, Iowa.…

Read MoreCardio Diagnostics Launches In-House Testing at New CLIA-Certified Iowa Laboratory
TAGRISSO

TAGRISSO Plus Savolitinib Improves Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer

TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a…

Read MoreTAGRISSO Plus Savolitinib Improves Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer
Almirall

Almirall Partners With CrystalO to Develop Novel Small Molecules for Medical Dermatology

Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology based in Barcelona, announced a collaboration and licensing agreement with Shenzhen CrystalO…

Read MoreAlmirall Partners With CrystalO to Develop Novel Small Molecules for Medical Dermatology